References
- Lotzova E. Analysis of effector mechanism in cancer. Current Opinion Immunol. 1989; 1: 904–909
- Panayotides P., Porwit A., Sjögren A. M., Wasserman J., Reizenstein P. Resistance of some leukemic blasts to lysis by lymphokine-activated killer (LAK) cells. Eur. J. Haematol. 1988; 40: 362–367
- Tahara T., Iseki R., Morishima Y., Yokomaku S., Ohno R., Saito H. Generation and characterization of lymphokine-activated killer cells against fresh human leukemia cells. Jpn. J. Cancer Res. 1988; 19: 390–399
- Palucka A. K., Porwit A., Reizenstein P. Resistance of leukemic blasts to lymphokine-activated killer (LAK)-mediated cytotoxicity is not related to their adhesion properties. Eur. J. Haematol. 1991; 47: 123–127
- Arienti F., Gambacorti-Passerini C, Borin L., Rivoltini L., Orazi A., Pogliani E. M., Corneo G., Parmiani G. Increased susceptibility to lymphokine-activated killer (LAK) lysis of relapsing vs newly diagnosed acute leukemic cells without changes in drug resistance or in the expression of adhesion molecules. Ann. Oncol. 1992; 3: 155–162
- Henkart P. A. Mechanism of lymphocyte-mediated cytotoxicity. Ann. Rev. Immunol. 1985; 3: 31–58
- Palucka A. K., Porwit A., Reizenstein P. Binding of leukemic blasts to various subpopulations of lymphokine-activated killer cells. Scand. J. Immunol. 1993; 37: 179–185
- Patarroyo M., Makgoba M. W. Leucocyte adhesion to cells in immune and inflammatory responses. Lancet 1989; ii: 1139–1142
- Timonen T., Gahmberg C. G., Patarroyo M. Participation of CD1 la-c/CD18, CD2 and RGD-binding receptors in endogenous and Interleukin-2 stimulated NK activity of CD3-negative large granular lymphocytes. Int. J. Cancer 1990; 6: 1035–1040
- Oblakowski P., Bello-Fernandez C, Reittie J. E., et al. Possible mechanism of selective killing of myeloid leukemic blasts cells by lymphokine-activated killer cells. Blood 1991; 77: 1996–2001
- Zanyk M. J., Banrejee D., McFarlane D. L. Transferrin receptor and 4F2 expression by NK-sensitive and NK-resistant tumour cell lines. Carcinogenesis 1988; 9: 1377–1381
- Bennett J. M., Catovsky D., Daniel M. T., et al. Proposals for the classification of acute leukemias, French-American-British (FAB) Cooperative group. Br. J. Haematol. 1976; 33: 451–458
- Palucka A. K., Porwit A., Reizenstein P. A supportive role of neural cell adhesion molecule (NCAM) in adhesion between leukemic blasts and cytotoxic lymphocytes. Scand. J. Immunol. 1992; 35: 399–406
- Roberts K., Lotze M. T. Interleukin 2 promotes conjugate formation by purified LAK precursors and T lymphocytes: evaluation of conjugates using flow cytometric techniques. J. Bio. Resp. Modif. 1988; 7: 249–266
- Callewaert D. M., Radcliff G., Waite R., LeFevre J., Poulik M. D. Characterization of effector-target conjugates for cloned human natural killer and human lymphokine-activated killer cells by flow cytometry. Cytometry 1991; 12: 666–676
- Quillet-Mary A., Cavarec L., Kermarrec N., et al. Target lysis by human LAK cells is critically dependent upon target binding properties, but LFA-1, LFA-3 and 1CAM-1 are not the major adhesion ligands on targets. Int. J. Cancer 1991; 47: 473–479
- Cesano A., Lista P., Bellone G., et al. Effect of human Interleukin 3 on the susceptibility of fresh leukemia cells to Interleukin-2-induced lymphokine-activated killing activity. Leukemia 1992; 6: 567–573
- Lotzova E., Savary C. A., Totpal K., Schachner J., Lich-tiger B., McCredie K. B., Freireich E. J. Highly oncolytic adherent lymphocytes: therapeutic relevance for leukemia. Leuk. Res. 1991; 4: 245–255